Heterocyclic Anticancer Agents

1. Auflage 2024
ISBN: 978-3-11-073926-8
Verlag: De Gruyter

Buch, Englisch, 512 Seiten, HC runder Rücken kaschiert, Format (B × H): 175 mm x 246 mm, Gewicht: 1180 g

Cancer is an incredibly diverse and difficult disease to treat, and even after decades of research there is no definitive cure. Therefore, it is highly crucial to search for novel and new organic molecules with high potency, low toxicity, and low mutagenicity with selective anticancer properties that are able to overcome frequently developed resistance to available drugs. Heterocyclic anticancer agents are an important class of drugs for cancer therapies. This book explores different heterocycles and their use as anticancer therapies. Topics covered include different heterocyclic derivatives, the impact of heterocycles on anticancer agent development, and naturally occurring heterocycles.

Zielgruppe

Libraries, academic researchers in pharmacology and biochemistry,

Autoren/Hrsg.

Krishna Banik, Bimal

Banerjee, Bubun

Banik, Bimal K.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Biochemie (med.)
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Naturwissenschaften Chemie Organische Chemie

Über Autor(innen)

Bimal K. Banik, Prince Mohammad Bin Fahd University, Al-Khobar, Saudi Arabia; Bubun Banerjee, Akal University, India.